Novo says Wegovy shot works in childhood obesity

News
Wegovy pen
Novo

Novo has published the results of a clinical trial of its Wegovy injection in children aged six to 12 with obesity, showing the drug was able to help them reduce their body mass index (BMI).

The full results of the STEP Young study showed that after 68 weeks of treatment with Wegovy (semaglutide) at a dose of 1.7 mg to 2.4 mg – dependent on the child's weight – there was an average BMI reduction of 17.4% compared to a 2.2% increase with placebo.

In addition, 80% of the children treated with the GLP-1 agonist achieved a 10% or greater reduction in BMI, and around 40% of them were no longer in the obese BMI category by the end of the follow-up period. The results were presented at ObesityWeek and simultaneously published in The New England Journal of Medicine.

Wegovy injection is already approved for the treatment of obesity in adolescents aged 12 and over and adults, and the new data could support a bid to extend the label into the younger age group.

According to recent data from the Centers for Disease Control and Prevention (CDC), approximately 21% of U.S. children and adolescents aged 2 to 19 have obesity, which translates to roughly 14.7 million to over 15 million young people, with 7% of them severely obese. The rate in the six-to-11 age range is also around 21%.

Most of the children in the STEP Young trial were classified as having severe (class II or III) obesity at baseline. Both treatment and placebo groups received lifestyle modification therapy during the trial, including a reduced-calorie diet and increased physical activity.

Alongside the improvements in BMI, children treated with Wegovy also had a positive effect on cardiometabolic measures like blood glucose control and insulin sensitivity, serum lipids, and blood pressure.

"Severe obesity can profoundly affect a child's physical health, emotional well-being, and daily life," said lead study author Ania Jastreboff of Yale School of Medicine and the Yale Obesity Research Center (Y-Weight).

"This chronic disease also increases the risk of many obesity-related complications that can emerge early and persist into adulthood," she added, noting that accompanying changes in cardiometabolic measures "may shift a child's trajectory back towards one of improving weight-related health."

Wegovy's closest competitor in the injectable weight loss category, Eli Lilly's market-leading Zepbound (tirzepatide), is not approved for use in children as yet, although the company is running trials in the 10 to 17 age bracket and presented results from one study – SURMOUNT-ADOLESCENTS – in children aged 12 to 17 at ObesityWeek.

Zepbound reduced BMI by an average of 21.4% in this adolescent population, with more than half no longer meeting the BMI criteria for obesity at 72 weeks.